Stay updated on Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial
Sign up to get notified when there's something new on the Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial page.

Latest updates to the Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial page
- Check3 days agoChange DetectedRevision updated to v3.4.3; the previous revision v3.4.2 has been removed.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe page now shows Revision: v3.4.2, and the older funding-related notice (v3.4.1) has been removed.SummaryDifference0.4%

- Check38 days agoChange DetectedAdded a government funding notice banner at the top of the page and updated the site revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check45 days agoChange DetectedAdded a glossary toggle, normalized capitalization for QC-related labels and No FEAR Act text, and updated the page revision to v3.4.0.SummaryDifference0.2%

- Check59 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 with no user-visible changes to the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check81 days agoChange DetectedThe page now lists updated study locations, adding Connecticut, Louisiana, Minnesota, Missouri, South Carolina, Tennessee, British Columbia, and Manitoba, and includes a revision note (v3.3.3). The previous location sections have been removed, reflecting an update to the location information presented on the page.SummaryDifference0.9%

Stay in the know with updates to Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial page.